Table 1.
Patient Demographics and Intraoperative Data
| Group C (n=35) | Group P (n=34) | P-values | |
|---|---|---|---|
| Age (years) | 56.77±4.35 | 54.91±3.69 | 0.055 |
| Sex (female/male, n) | 15/20 | 12/22 | 0.624 |
| Body weight (kg) | 74.27±8.23 | 78.04±9.51 | 0.083 |
| BMI (kg·m–2) | 25.04±2.39 | 25.25±2.98 | 0.747 |
| ASA Ⅰ to Ⅱ (n) | 7/28 | 10/24 | 0.413 |
| FEV1/FVC (%) | 89.67±3.28 | 90.39±3.11 | 0.353 |
| Comorbidity, n (%) | 0.785 | ||
| Hypertension | 15 (42.86%) | 14 (41.18%) | |
| Diabetes mellitus | 5 (14.29%) | 8 (23.53%) | |
| Coronary heart disease | 7 (20.00%) | 9 (26.47%) | |
| COPD/asthma | 2 (5.71%) | 1 (2.94%) | |
| Type of surgery, n (%) | 1.000 | ||
| Lobectomy | 25 (71.43%) | 24 (70.59%) | |
| Segmentectomy | 6 (17.14%) | 7 (20.59%) | |
| Wedge resection | 4 (11.43%) | 3 (8.82%) | |
| Preoperative CCRT, n (%) | 8 (22.86%) | 6 (17.65%) | 0.766 |
| Duration of surgery (min) | 128.78±12.49 | 119.70±10.82 | 0.142 |
| Duration of anaesthesia (min) | 147.49±18.19 | 138.30±21.54 | 0.060 |
| Intraoperative bleeding (mL) | 87.53±23.87 | 95.03±21.82 | 0.173 |
| Fluids (mL) | 1463.25±108.33 | 1395.00±88.21 | 0.076 |
| Urine output (mL) | 357.90±56.48 | 339.35±43.76 | 0.133 |
| Dexmedetomidine (μg·kg–1·h–1) | 0.43±0.12 | 0.32±0.10** | 0.001 |
| Remifentanil (μg·kg–1·min–1) | 0.18±0.05 | 0.14±0.04** | 0.001 |
| Sevoflurane (%) | 2.39±1.28 | 1.78±1.01* | 0.032 |
| Number of using vasoactive agent n (%) | 27 (77.14%) | 18 (52.94%)* | 0.045 |
| Cisatracurium dosage (mg·kg–1) | 0.25±0.04 | 0.24±0.02 | 0.196 |
Notes: Variables presented as mean ± SD or number of patients n (%). *P < 0.05 vs Group C; **P < 0.01 vs Group C.
Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiology; FEV1/FVC, forced vital capacity rate of one second/forced vital capacity; CCRT, concurrent chemoradiation therapy; PACU, post-anesthesia care unit.